Compare IOVA & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | NUWE |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.6M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | IOVA | NUWE |
|---|---|---|
| Price | $2.67 | $2.06 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $10.45 | N/A |
| AVG Volume (30 Days) | ★ 12.3M | 40.7K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,425,000.00 | $8,167,999.00 |
| Revenue This Year | $60.71 | N/A |
| Revenue Next Year | $59.52 | $10.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 175.62 | N/A |
| 52 Week Low | $1.64 | $1.71 |
| 52 Week High | $7.78 | $70.14 |
| Indicator | IOVA | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 56.95 | 44.01 |
| Support Level | $2.69 | $1.71 |
| Resistance Level | $2.89 | $2.20 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 57.53 | 48.67 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.